mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Report

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68040-083-7
Number of Report Pages: 144
Format: PDF, Horizon Databook

Historical Range: 2018 - 2023
Forecast Period: 2024 - 2030
Industry: Healthcare

Market Segmentation

mRNA Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)
- Viral Vaccines
- Protein Replacement Therapies
- Cancer Immunotherapies
mRNA Therapeutics CDMO Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Infectious Diseases
- Metabolic & Genetic Diseases
- Cardiovascular & Cerebrovascular Diseases
mRNA Therapeutics CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Biotech Companies
- Pharmaceutical companies
- Government & Academic Research Institutes
mRNA Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Viral Vaccines
    - Protein Replacement Therapies
    - Cancer Immunotherapies
  - North America Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Metabolic & Genetic Diseases
    - Cardiovascular & Cerebrovascular Diseases
  - North America End-Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Biotech Companies
    - Pharmaceutical companies
    - Government & Academic Research Institutes
  - U.S.
    - U.S. Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - U.S. Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - U.S. End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Canada
    - Canada Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Canada Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Canada End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
- Europe
  - Europe Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Viral Vaccines
    - Protein Replacement Therapies
    - Cancer Immunotherapies
  - Europe Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Metabolic & Genetic Diseases
    - Cardiovascular & Cerebrovascular Diseases
  - Europe End-Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Biotech Companies
    - Pharmaceutical companies
    - Government & Academic Research Institutes
  - UK
    - UK Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - UK Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - UK End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Germany
    - Germany Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Germany Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Germany End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - France
    - France Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - France Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - France End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Italy
    - Italy Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Italy Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Italy End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Spain
    - Spain Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Spain Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Spain End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Sweden
    - Sweden Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Sweden Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Sweden End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Denmark
    - Denmark Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Denmark Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Denmark End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Norway
    - Norway Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Norway Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Norway End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
- Asia Pacific
  - Asia Pacific Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Viral Vaccines
    - Protein Replacement Therapies
    - Cancer Immunotherapies
  - Asia Pacific Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Metabolic & Genetic Diseases
    - Cardiovascular & Cerebrovascular Diseases
  - Asia Pacific End-Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Biotech Companies
    - Pharmaceutical companies
    - Government & Academic Research Institutes
  - Japan
    - Japan Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Japan Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Japan End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - China
    - China Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - China Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - China End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - India
    - India Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - India Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - India End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - South Korea
    - South Korea Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - South Korea Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - South Korea End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Australia
    - Australia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Australia Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Australia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Indonesia
    - Indonesia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Indonesia Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Indonesia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
- Latin America
  - Latin America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Viral Vaccines
    - Protein Replacement Therapies
    - Cancer Immunotherapies
  - Latin America Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Metabolic & Genetic Diseases
    - Cardiovascular & Cerebrovascular Diseases
  - Latin America End-Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Biotech Companies
    - Pharmaceutical companies
    - Government & Academic Research Institutes
  - Brazil
    - Brazil Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Brazil Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Brazil End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Mexico
    - Mexico Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Mexico Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Mexico End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Argentina
    - Argentina Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Argentina Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Argentina End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
- Middle East and Africa
  - Middle East and Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Viral Vaccines
    - Protein Replacement Therapies
    - Cancer Immunotherapies
  - Middle East and Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
    - Infectious Diseases
    - Metabolic & Genetic Diseases
    - Cardiovascular & Cerebrovascular Diseases
  - Middle East and Africa End-Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Biotech Companies
    - Pharmaceutical companies
    - Government & Academic Research Institutes
  - South Africa
    - South Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - South Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - South Africa End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Saudi Arabia
    - Saudi Arabia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Saudi Arabia Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Saudi Arabia End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - UAE
    - UAE Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - UAE Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - UAE End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institutes
  - Kuwait
    - Kuwait Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Viral Vaccines
      - Protein Replacement Therapies
      - Cancer Immunotherapies
    - Kuwait Indication Outlook (Revenue in USD Million, 2018 - 2030)
      - Infectious Diseases
      - Metabolic & Genetic Diseases
      - Cardiovascular & Cerebrovascular Diseases
    - Kuwait End-Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Biotech Companies
      - Pharmaceutical companies
      - Government & Academic Research Institut

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.